Format

Send to

Choose Destination
Trends Cardiovasc Med. 2016 Apr;26(3):221-8. doi: 10.1016/j.tcm.2015.06.004. Epub 2015 Jun 15.

Angiotensin receptor blockers: Focus on cardiac and renal injury.

Author information

1
Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Higashijima, Akiha-Ku, Niigata, Japan.
2
Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Higashijima, Akiha-Ku, Niigata, Japan; Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX.
3
Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX.
4
Department of Gastroenterology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
5
Department of Cardiology, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
6
Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Higashijima, Akiha-Ku, Niigata, Japan. Electronic address: watanabe@nupals.ac.jp.

Abstract

Angiotensin II, an important component of renin angiotensin system, is a potent vasopressor and its actions are mostly mediated via angiotensin II type 1 receptor (AT1R) and role of AT2R in counterbalancing the actions of AT1R stimulation are under extensive research. In addition to its physiological actions, angiotensin II plays important roles in the pathogenesis of atherosclerosis, hypertension, left ventricular hypertrophy, and heart failure. The effects of angiotensin II can be blocked by either suppressing its production by blocking angiotensin converting enzyme or by antagonizing its actions on AT1R using angiotensin II receptor blockers (ARBs). Instead of the extensive use of ARBs in the treatment of various cardiovascular diseases, proper selection of a particular ARB is crucial as the clinical condition of individual patient is different and also their economic status would play an essential role in medication compliance. Thus a critical review of the proven and promising actions of ARBs against various pathological conditions will be of great importance for the clinicians as well as for the researchers.

KEYWORDS:

Angiotensin receptor blocker; Diabetes mellitus; Heart failure; Hypertension; Renin angiotensin system

PMID:
26169314
DOI:
10.1016/j.tcm.2015.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center